About Sellas Life Sciences Group Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.sellaslifesciences.com/
Frequently Asked Questions
What is the 52-week range for SLS?
The 52-week high is $15.8765 and the 52-week low is $1.39.
What is the P/E ratio for SLS?
The P/E ratio data is currently unavailable.
What is the dividend yield for SLS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -35.91%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -736.21%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.58.
Analyst Recommendation Trends
Wall Street analyst consensus for SLS over the last few months:
Latest SLS News
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.
SLS Stock Snaps 3-Quarter Winning Streak — Retail Traders Speculate On Buyout, Eye Lease Through 2027
Retail investors speculated that Sellas’ office lease through September 2027 provides stability for clinical results and potential deal discussions.
Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3
Shares of Sellas Life Sciences Group Inc. (NASDAQ:SLS) nosedived by 16.6 percent in the third quarter of the year—from $14.76 on June 30 to $12.31 on Wednesday—as sentiment was dragged down by the delays and uncertainties surrounding the clinical results of its treatment candidate for acute myeloid leukemia (AML). In Wednesday’s trading alone, the stock […]
Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?
SELLAS Life Sciences Group, Inc. recently reported preclinical data at an AACR pancreatic cancer conference showing its CDK9 inhibitor SLS009 induced meaningful cancer cell death in MYC-amplified, daraxonrasib-resistant pancreatic ductal adenocarcinoma organoid models, both alone and in combinations. The findings highlight SLS009’s potential to address RAS inhibitor resistance and show synergistic effects when paired with BET inhibitor ZEN3694 at relatively low exposure levels. We’ll now...
SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer Data
SELLAS Life Sciences Group has delivered a very large 3 year return, which puts a spotlight on whether the current share price around US$11.51 still lines up with what its balance sheet is worth on paper. With that kind of move behind it and new cancer therapy data in play, the question now is how much value investors are effectively placing on SELLAS' book value. Over the past 3 years, the stock has gained roughly 7x. This makes the relationship between its recent share price performance...
SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data
SELLAS Life Sciences Group (SLS) presented new preclinical data on September 25, 2026, highlighting its CDK9 inhibitor SLS009 in pancreatic cancer organoid models at an AACR pancreatic cancer conference. SELLAS Life Sciences Group shares trade at US$11.51 after a 1-day share price return that declined 0.69%, extending a 30-day share price drop of 12.87%. Yet the 1-year total shareholder return is very large at more than 6x and the 3-year total shareholder return is also very large, hinting...
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered
SLS investors have been closely watching for two key developments: late-stage REGAL study data for the company’s GPS cancer vaccine in acute myeloid leukemia and a decision on whether SLS009 will advance into human trials for pancreatic cancer.
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009
SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Models
SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased
SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial
Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.
Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight
DelveInsight's Cancer Vaccines Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Lung Cancer (NSCLC), Bladder Cancer, Prostate Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Cervical Cancer, and Other Solid Tumors. The selected indications are based on approved therapies and ongoing pipeline activity.
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
Get insights into the top gainers and losers of Monday's pre-market session.
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck
ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data
SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. | +1,065,000 | - | - |
| 2026-01-07 | Varian John | +50,000 | - | - |
| 2026-01-07 | CICIC DRAGAN | +300,000 | - | - |
| 2026-01-07 | Burns John Thomas | +300,000 | - | - |
| 2026-01-07 | Kalin Katherine Bach | +50,000 | - | - |
| 2026-01-07 | Wasman Jane | +50,000 | - | - |
| 2026-01-07 | SCHEINBERG DAVID A | +50,000 | - | - |
| 2026-01-07 | VAN NOSTRAND ROBERT L | +50,000 | - | - |
| 2025-12-03 | CICIC DRAGAN | -63,800 | $1.5 | $95,700 |
| 2025-12-03 | Burns John Thomas | -58,592 | $1.5 | $87,888 |
| 2025-12-03 | Stergiou Angelos M. | -187,066 | $1.5 | $280,599 |
| 2025-11-19 | Kalin Katherine Bach | +63,400 | $1.59 | $100,806 |